Kilitch Drugs Quarterly Results
Kilitch Drugs quarterly results. In Mar 2026, Kilitch Drugs (KILITCH) reported revenue ₹90 Cr and net profit ₹15 Cr — revenue +42.9% YoY. For annual financials, live price and key ratios, visit KILITCH stock price BSE.
KILITCH Quarterly Results — Revenue, Profit & EPS Highlights
Kilitch Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review KILITCH P/E ratio to evaluate earnings-based valuation against sector peers.
- Revenue of ₹90 Cr in Mar 2026 (+87.5% vs Jun 2026, +42.9% vs Mar 2025)
- Net Profit of ₹15 Cr in Mar 2026 (+650.0% vs Jun 2026, +50.0% vs Mar 2025)
- EBITDA of ₹23 Cr in Mar 2026 (+283.3% vs Jun 2026)
- Operating Margin of 25.0% in Mar 2026 (+18.0pp vs Jun 2026)
- Earnings Per Share of ₹4.24 in Mar 2026 (+410.8% vs Jun 2026)
Kilitch Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
KILITCH quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 90 | 48 | 56 | 63 | 46 | 87.5% | 42.9% |
| Net Profit (₹ Cr) | 15 | 2 | 8 | 10 | 2 | - | - |
| EBITDA (₹ Cr) | 23 | 6 | 12 | 16 | 6 | - | - |
| EPS (₹) | 4.24 | 0.83 | 4.97 | 6.47 | 1.88 | - | - |
| Operating Margin (%) | 25.0% | 7.0% | 10.0% | 24.0% | 8.0% | - | - |
KILITCH Share Price Trend — 1-Year Movement Across Quarterly Results
Kilitch Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check KILITCH market capitalization to track the company's total market size over time.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
KILITCH vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Kilitch Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores